**Pattela Indian pharma sector-from revenue to growth model**

**Review comments:**

**Review comments**:

1. It is written in an erudite fashion. But basically it is some kind of predetermined  ideological narrative of the pharma boom in India, which I am loath to accept  - my bad as I said.

And the connection to medical ethics (in this case ethics of the principal players basically the capital class) is tenous.

It may be grist to the mill of a certain type of leftist narrative. I do not agree that the history of Indian pharma cos post 1970 can be seen in binaries of revenue and growth - it is an artificial divide to say:

A revenue-based business model is one in which the value of the company is determined by profits which is, *“how much money they actually make over the amount expended*” (4: p 40) While in a growth-based business model the focus is on *‘how much potential there is for future earning over and above the present rate of earning so that it can be translated into shareholders value*’

The only statement in the author's Concluding Remarks that I agree with is

"**The perusal of growth as a principle of macro economy takes various forms when it comes to operate at the micro level, especially at the sectoral level. The micro level sectoral specificities and their nuances actually complicate the situation than it might be theoretically envisaged."**

If it so nuanced then why build this narrative? Especially when Indian cos are 80% of the market. And MNCs are 20%.

So I do not want to discourage/destroy the career of a young  person, so it may be good to take the opinion of a second more scholarly person like Sudip Chaudhuri.

-------------------------------------------------------